73,844 Shares in Metagenomi, Inc. (NASDAQ:MGX) Purchased by Spire Wealth Management

Spire Wealth Management purchased a new stake in shares of Metagenomi, Inc. (NASDAQ:MGX) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 73,844 shares of the company’s stock, valued at approximately $267,000. Spire Wealth Management owned approximately 0.20% of Metagenomi at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. SG Americas Securities LLC purchased a new position in Metagenomi in the fourth quarter worth about $43,000. BNP Paribas Financial Markets lifted its stake in shares of Metagenomi by 130.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 12,799 shares of the company’s stock valued at $28,000 after purchasing an additional 7,256 shares during the last quarter. Virtu Financial LLC purchased a new position in shares of Metagenomi in the 3rd quarter worth approximately $33,000. Verition Fund Management LLC bought a new position in shares of Metagenomi during the 3rd quarter valued at approximately $82,000. Finally, Marquette Asset Management LLC bought a new position in shares of Metagenomi during the 4th quarter valued at approximately $184,000.

Wall Street Analyst Weigh In

Several research firms have commented on MGX. Chardan Capital reaffirmed a “buy” rating and set a $15.00 price objective on shares of Metagenomi in a research note on Wednesday, November 20th. HC Wainwright raised their target price on shares of Metagenomi from $7.00 to $14.00 and gave the stock a “buy” rating in a report on Tuesday, December 10th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $16.67.

Metagenomi Stock Down 4.7 %

Shares of Metagenomi stock opened at $2.64 on Friday. The stock’s fifty day moving average is $3.08 and its two-hundred day moving average is $2.78. Metagenomi, Inc. has a 52 week low of $1.61 and a 52 week high of $12.74.

Metagenomi Profile

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.